Q-omics provides the consensus-scored MIR615 profile across patient tissues and cancer cell-line models. MIR615 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR615 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR615 RNA expression shows 6,195 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight LIHC, BRCA, and KIRC as cancer lineages where MIR615 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR615 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR615 survival associations across molecular data types. MIR615 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR615 RNA expression–survival associations across cancer types. High MIR615 expression shows unfavorable associations in LIHC, UVM, CHOL, READ, KIRC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR615 RNA expression.
This table summarizes MIR615 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR615. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR615 shows lower tumor expression in UCEC and higher tumor expression in BRCA and PRAD. The BRCA box plot shows higher MIR615 RNA expression in tumor versus normal tissue (log2 FC = +0.141, t-test p < 0.001).
This table shows molecular features associated with MIR615 in patient tissues and cancer cell lines. In patient samples, MIR615 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
